Figure 3From: Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationClinical response to treatment is independent of the presence of antiadalimumab antidrug antibodies. Antiadalimumab antidrug antibodies (ADAbs) at the end of treatment, 2Â weeks after the last injection, were not different between patients treated with 12 vs. 24Â weeks of adalimumab (A) or between responders vs. nonresponders (B).Back to article page